New technologies in therapeutic antibody development

被引:53
作者
Brekke, OH
Loset, GÅ
机构
[1] Affitech New Technol, N-0349 Oslo, Norway
[2] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway
关键词
D O I
10.1016/j.coph.2003.05.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of therapeutic antibodies took a sharp turn with the introduction of phage display technology over a decade ago. Antibodies are used in a whole range of disease fields, such as autoimmunity, cancer, inflammation and infectious diseases. Now, the first antibody derived from phage display technology has been approved in the US by the Food and Drug Administration. The antibody industry is continuously developing new and robust discovery platforms and novel antibody formats, which points to the versatility of antibodies as therapeutic and diagnostic agents.
引用
收藏
页码:544 / 550
页数:7
相关论文
共 60 条
  • [1] Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
    Begent, RHJ
    Verhaar, MJ
    Chester, KA
    Casey, JL
    Green, AJ
    Napier, MP
    HopeStone, LD
    Cushen, N
    Keep, PA
    Johnson, CJ
    Hawkins, RE
    Hilson, AJW
    Robson, L
    [J]. NATURE MEDICINE, 1996, 2 (09) : 979 - 984
  • [2] Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations
    Behr, TM
    Goldenberg, DM
    Becker, W
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (02) : 201 - 212
  • [3] Bell SJ, 2000, ALIMENT PHARM THER, V14, P501
  • [4] ACTIVATION OF COMPLEMENT BY AN IGG MOLECULE WITHOUT A GENETIC HINGE
    BREKKE, OH
    MICHAELSEN, TE
    SANDIN, R
    SANDLIE, I
    [J]. NATURE, 1993, 363 (6430) : 628 - 630
  • [5] A LARGE ARRAY OF HUMAN MONOCLONAL-ANTIBODIES TO TYPE-1 HUMAN-IMMUNODEFICIENCY-VIRUS FROM COMBINATORIAL LIBRARIES OF ASYMPTOMATIC SEROPOSITIVE INDIVIDUALS
    BURTON, DR
    BARBAS, CF
    PERSSON, MAA
    KOENIG, S
    CHANOCK, RM
    LERNER, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (22) : 10134 - 10137
  • [6] PEGylated antibodies and antibody fragments for improved therapy: a review
    Chapman, AP
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (04) : 531 - 545
  • [7] Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial
    Choy, EHS
    Hazleman, B
    Smith, M
    Moss, K
    Lisi, L
    Scott, DGI
    Patel, J
    Sopwith, M
    Isenberg, DA
    [J]. RHEUMATOLOGY, 2002, 41 (10) : 1133 - 1137
  • [8] Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells
    Cochlovius, B
    Kipriyanov, SM
    Stassar, MJJG
    Christ, O
    Schuhmacher, J
    Strauss, G
    Moldenhauer, G
    Little, M
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (02) : 888 - 895
  • [9] Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs
    Conrath, KE
    Lauwereys, M
    Wyns, L
    Muyldermans, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) : 7346 - 7350
  • [10] Signaling antibodies in cancer therapy
    Cragg, MS
    French, RR
    Glennie, MJ
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (05) : 541 - 547